We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases
Platform | Substack | Pricing | Freemium | Publishes | Daily |
---|---|---|---|---|---|
Issues | 76 | Subscribers | Read | drugdevletter.com |
Curious about how many subscribers The Drug Development Letter has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over one million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
How this newsletter ranks in the official Substack charts.
#164 | |
#232 |
Recent posts by this newsletter. Browse the email archive.
(Here is the thread.)
### Background about “Lu-PSMA”
The 10-year results of first-line immune checkpoint inhibitors in melanoma are truly remarkable. They have just been published in the New England Journal of Medicine (also accessible here).
In the past decade, an area of research that has attracted much interest from scientists has been the development of CDK4/6 inhibitors (CDK4/6i) for neoadjuvant HR-positive, HER2-negative early breast cancer. Six years ago, in 2018, 16 tria...
The writers behind this newsletter.
Hematology Oncology Medicine Health Policy Epidemiology Professor
Medical oncologist based in Geneva University Hospital (Switzerland), I joined Vinay Prasad's research lab (@vkprasadlab) at University of California San Francisco (UCSF) in November 2021.
Internist-hematologist/medical oncologist Curaçao
Pharmacist Medicine & Society (PharmD-PhD), National Funder’s Committee for Evaluation of Specialised Medicines and Companion Diagnostics, CZ. Associate Professor of Medical Oncology and Accessibility of Medicine, LUMC, NL
Medical Immunologist with great interest for achieving true value healthcare including social justice and DEI. Medical education of young doctors is essential for achieving the necessary changes in healthcare.
You can find recent issues that have been published by The Drug Development Letter on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to The Drug Development Letter, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Drug Development Letter as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Drug Development Letter using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Similar Newsletters to see other publications like The Drug Development Letter. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.